AdultPediatricDosage Forms & Strengths tablet 1mg 2mg 4mg Rheumatoid Arthritis Indicated for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies May be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) 2 mg PO qDay Alopecia Areata Indicated for adults with severe alopecia areata 2 mg PO qDay; increase to 4 mg qDay if inadequate response With nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider 4 mg qDay Once adequate response achieved with 4 mg/day, decrease to 2 mg/day COVID-19 Indicated for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) 4 mg PO qDay Recommended treatment duration is 14 days or until hospital discharge, whichever comes first Dosage Modifications Absolute lymphocyte count (ALC) RA or alopecia areata ALC ≥500 cells/mm3: Maintain dose ALC <500 cells/mm3: Avoid initiation or interrupt dosing until ALC ≥500 cells/mm3 ​COVID-19 ALC ≥200 cells/mm3: Maintain dose ALC <200 cells/mm3: Avoid initiation or interrupt dosing until ALC ≥200 cells/mm3 Absolute neutrophil count (ANC) RA or alopecia areata ANC ≥1000 cells/mm3: Maintain dose ANC <1000 cells/mm3: Avoid initiation or interrupt dosing until ANC ≥1000 cells/mm3 COVID-19 ANC ≥500 cells/mm3: Maintain dose ANC <500 cells/mm3: Avoid initiation or interrupt dosing until ANC ≥500 cells/mm3 Anemia RA or alopecia areata Hgb ≥8 g/dL: Maintain dose Hgb <8 g/dL: Avoid initiation or interrupt dosing until Hgb ≥8 g/dL Renal impairment RA Mild (eGFR 60 to <90 mL/min/1.73 m2): No dose adjustment required Moderate (eGFR 30 to <60 mL/min/1.73 m2): Decrease to 1 mg/day Severe (eGFR <30 mL/min/1.73 m2): Not recommended (not studied) Alopecia areata Mild (eGFR 60 to <90 mL/min/1.73 m2): No dose adjustment required Moderate (eGFR 30 to <60 mL/min/1.73 m2): Reduce dose by 50% Severe (eGFR <30 mL/min/1.73 m2): Not recommended COVID-19 Mild (eGFR 60 to <90 mL/min/1.73 m2): No dose adjustment Moderate (eGFR 30 to <60 mL/min/1.73 m2): Decrease to 2 mg/day Severe (eGFR 15 to <30 mL/min/1.73 m2): Decrease to 1 mg/day eGFR <15 mL/min/1.73 m2, patients on dialysis, have end-stage renal disease, or have acute kidney injury: Not recommended Hepatic impairment RA or alopecia areata Interrupt if ALT/AST increased and drug-induced liver injury (DILI) suspected, until DILI diagnosis excluded Mild or moderate: No dose adjustment required Severe: Not recommended COVID-19 Interrupt if ALT/AST increased and DILI suspected, until DILI diagnosis excluded Increased ALT/AST: Consider interruption until the diagnosis of drug-induced liver injury is excluded Severe: Not studied; use only if benefits outweigh risks Coadministration with strong organic anion transporter 3 (OAT3) inhibitors (eg, probenecid) If recommended dose is 4 mg/day, reduce to 2 mg/day If recommended dose is 2 mg/day, reduce to 1 mg/day If recommended dose is 1 mg/day, consider discontinuing probenecid Dosing Considerations Consider following evaluations before initiating Active and latent tuberculosis (TB) infection: Do not give to patients with active TB; if latent infection positive in patients with rheumatoid arthritis, consider treatment for TB before initiating Screen for viral hepatitis in accordance with clinical guidelines Baseline hepatic and renal function: Assess baseline values and monitor for laboratory changes; modify dosage based on hepatic and renal impairment, and laboratory abnormalities Complete blood cell count (CBC) Assess baseline to determine whether treatment can be initiated Rheumatoid arthritis: Not recommended with ALC <500 cells/μL, ANC <1000 cells/μL, or hemoglobin level <8 g/dL COVID-19: Not recommended with ALC <200 cells/μL, ANC <500 cells/μL Monitor CBC during treatment and modify dosage as recommended RA or alopecia areata Avoid in patients with active, serious infection, including localized infections; if serious infection occurs, withhold treatment Update immunizations in agreement with current immunization guidelines before initiating Limitations of use: Not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic DMARDs, or with potent immunosuppressants (eg, azathioprine, cyclosporine) Dosage Forms & Strengths tablet 1mg 2mg 4mg COVID-19 (EUA) November 19, 2020: Emergency use authorization (EUA) issued by the FDA for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized patients aged 2 to <18 years who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) <2 years: Not authorized 2 to <9 years: 2 mg PO qDay 9 to <18 years: 4 mg PO qDay Recommended treatment duration is 14 days or until hospital discharge, whichever comes first; optimal treatment duration unknown Dosage Modifications Absolute lymphocyte count (ALC) ​COVID-19 ALC ≥200 cells/mm3: Maintain dose ALC <200 cells/mm3: Avoid initiation or interrupt dosing until ALC ≥200 cells/mm3 Absolute neutrophil count (ANC) COVID-19 ANC ≥500 cells/mm3: Maintain dose ANC <500 cells/mm3: Avoid initiation or interrupt dosing until ANC ≥500 cells/mm3 Renal impairment COVID-19 (2-9 years) eGFR ≥60 mL/min/1.73 m2: No dose adjustment eGFR 30 to <60 mL/min/1.73 m2: Decrease to 1 mg/day eGFR 15 to <30 mL/min/1.73 m2: Not recommended eGFR <15 mL/min/1.73 m2, patients on dialysis, have end-stage renal disease, or have acute kidney injury: Not recommended COVID-19 (≥9 years) eGFR ≥60 mL/min/1.73 m2: No dose adjustment eGFR 30 to <60 mL/min/1.73 m2: Decrease to 2 mg/day eGFR 15 to <30 mL/min/1.73 m2: Decrease to 1 mg/day eGFR <15 mL/min/1.73 m2, patients on dialysis, have end-stage renal disease, or have acute kidney injury: Not recommended Hepatic impairment COVID-19 Increased ALT/AST: Consider interruption until the diagnosis of drug-induced liver injury is excluded Severe: Not studied; use only if benefits outweigh the risks Coadministration with strong organic anion transporter 3 (OAT3) inhibitors (eg, probenecid) COVID-19 If recommended dose is 4 mg/day, reduce to 2 mg/day If recommended dose is 2 mg/day, reduce to 1 mg/day If recommended dose is 1 mg/day, consider discontinuing probenecid Dosing Considerations COVID-19 Evaluate baseline eGFR, liver enzymes, and CBC count to determine treatment suitability and dose Closely monitor patients with abnormal baseline and post-baseline laboratory values Not recommended with known active TB Data are limited in patients receiving systemic corticosteroids Has not been studied in combination with other JAK inhibitors or with biologic DMARDs (biologic treatments targeting cytokines, B-cells, or T-cells) EUA for patients hospitalized or in ACS Authorized for emergency use to treat certain hospitalized patients with COVID-19 Authorization clarifies that individuals determined as being appropriate for acute inpatient hospitalization and who are admitted or transferred to an alternate care site (ACS) that can provide acute care that is comparable to general inpatient hospital care are within the terms and conditions of the EUA An ACS is intended to provide additional hospital surge capacity and capability for communities overwhelmed by patients with COVID-19 Interaction CheckerEnter a drug name and baricitinibNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)upadacitinibbaricitinib, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.Serious - Use Alternative (58)abataceptbaricitinib, abatacept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.adalimumabbaricitinib, adalimumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.adenovirus types 4 and 7 live, oralbaricitinib decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib.ado-trastuzumab emtansinebaricitinib, ado-trastuzumab emtansine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.anakinrabaricitinib, anakinra. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.axicabtagene ciloleucelbaricitinib, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.azathioprinebaricitinib, azathioprine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.balsalazidebalsalazide will increase the level or effect of baricitinib by decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended.BCG vaccine livebaricitinib decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib.brexucabtagene autoleucelbaricitinib, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.canakinumabbaricitinib, canakinumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.certolizumab pegolbaricitinib, certolizumab pegol. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.ciltacabtagene autoleucelbaricitinib, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.cyclosporinebaricitinib, cyclosporine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.deferipronebaricitinib, deferiprone. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.diflunisaldiflunisal will increase the level or effect of baricitinib by decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended.etanerceptbaricitinib, etanercept. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.ethacrynic acidethacrynic acid will increase the level or effect of baricitinib by decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended.fingolimodbaricitinib, fingolimod. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.golimumabbaricitinib, golimumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.idecabtagene vicleucelbaricitinib, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.infliximabbaricitinib, infliximab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.influenza virus vaccine quadrivalent, intranasalbaricitinib decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib.irbesartanirbesartan will increase the level or effect of baricitinib by decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended.ketorolacketorolac will increase the level or effect of baricitinib by decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended.lisocabtagene maraleucelbaricitinib, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles mumps and rubella vaccine, livebaricitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib.measles, mumps, rubella and varicella vaccine, livebaricitinib decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines with baricitinib. Update immunizations in agreement with current immunization guidelines before initiating baricitinib.meclofenamatemeclofenamate will increase the level